AI startups dominated U.S. funding this week, capturing the lion's share of megadeals across the market. The trend reflects ongoing investor appetite for artificial intelligence infrastructure and applications, even as venture capital remains selective about which companies receive large checks.
Biotech emerged as the second-largest funding category for the week, signaling that life sciences innovation continues to attract substantial capital despite AI's outsized headlines. The dual focus on AI and biotech underscores a broader pattern in venture capital: investors are concentrating resources on sectors with defensible technology moats and clear paths to massive markets.
The dominance of AI funding rounds reflects the sector's ability to command attention from mega-funds and growth investors. Companies building LLM infrastructure, enterprise AI tools, and AI-powered services have maintained fundraising momentum through 2024 and into 2025, even as earlier-stage AI companies face increased scrutiny over unit economics and customer acquisition costs.
Biotech's appearance among the week's top funding categories carries weight. Investors backing life sciences startups are betting on genomics, drug discovery platforms, and therapeutic development. These rounds typically involve later-stage companies with established clinical pipelines or platform technology with broad applications.
The bifurcation between AI and biotech reflects how venture capital allocates capital to "pick and shovel" opportunities versus outcome-focused bets. AI infrastructure plays appeal to investors seeking explosive growth and network effects. Biotech rounds tend to be smaller in aggregate but represent deeper commitments to companies with longer development timelines and higher capital requirements per company.
This week's funding patterns align with historical venture trends. When one sector gains momentum, it attracts follow-on capital and syndication from established firms. AI's dominance in headlines and its perceived transformative potential give it outsized weight in dealflow decisions. Biotech, by contrast, maintains steady funding through specialized biotech VCs